The DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.
Targeting the Cell Cycle: A New Approach to Cancer Therapy
Abstract
The cell cycle represents a series of tightly integrated events that allow the cell to grow and proliferate. Critical parts of the cell cycle machinery are the cyclin-dependent kinases (CDKs), which, when activated, provide a means for the cell to move from one phase of the cell cycle to the next. The CDKs are regulated positively by cyclins and regulated negatively by naturally occurring CDK inhibitors (CDKIs). Cancer represents a dysregulation of the cell cycle such that cells that overexpress cyclins or do not express the CDKIs continue to undergo unregulated cell growth. The cell cycle also serves to protect the cell from DNA damage. Thus, cell cycle arrest, in fact, represents a survival mechanism that provides the tumor cell the opportunity to repair its own damaged DNA. Thus, abrogation of cell cycle checkpoints, before DNA repair is complete, can activate the apoptotic cascade, leading to cell death. Now in clinical trials are a series of targeted agents that directly inhibit the CDKs, inhibit unrestricted cell growth, and induce growth arrest. Recent attention has also focused on these drugs as inhibitors of transcription. In addition, there are now agents that abrogate the cell cycle checkpoints at critical time points that make the tumor cell susceptible to apoptosis. An understanding of the cell cycle is critical to understanding how best to clinically develop these agents, both as single agents and in combination with chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
The DNA damage response: putting checkpoints in perspective
Zhou, B.-B. S., & Elledge, S. J. (2000) · Nature · doi:10.1038/35044005 · Cited by 3,213
Hartwell, L. H., & Kastan, M. B. (1994) · Science · doi:10.1126/science.7997877 · Cited by 2,535
Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V., Manegold, C., Scagliotti, G., Rosell, R., Oliff, I., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,707
To cycle or not to cycle: a critical decision in cancer
Malumbres, M., & Barbacid, M. (2001) · Nature Reviews Cancer · doi:10.1038/35106065 · Cited by 1,468
A Restriction Point for Control of Normal Animal Cell Proliferation
Pardee, A. B. (1974) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.71.4.1286 · Cited by 1,415
The Pezcoller lecture: cancer cell cycles revisited.
Sherr, C. J. (2000) · PubMed · Cited by 1,409
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236
Cyclin D1 Expression Is Regulated Positively by the p42/p44 and Negatively by the p38/HOG Pathway
Lavoie, J. N., L'Allemain, G., Brunet, A., Müller, R., & Pouysségur, J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.34.20608 · Cited by 1,211
Graña, X., & Reddy, E. P. (1995) · PubMed · Cited by 1,139
Richon, V. M., Sandhoff, T. W., Rifkind, R. A., & Marks, P. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180316197 · Cited by 1,090
The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis
Falck, J., Mailand, N., Syljuåsen, R. G., Bartek, J., & Lukas, J. (2001) · Nature · doi:10.1038/35071124 · Cited by 1,085
Harrington, E. A., Bebbington, D., Moore, J., Rasmussen, R. K., Ajose-Adeogun, A. O., Nakayama, T., Graham, J. A., Demur, C., Hercend, T., Diu-Hercend, A., et al. (2004) · Nature Medicine · doi:10.1038/nm1003 · Cited by 965
Blangy, A., Lane, H. A., d'Hérin, P., Harper, M., Kress, M., & Niggt, E. A. (1995) · Cell · doi:10.1016/0092-8674(95)90142-6 · Cited by 952
Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles
Glover, D. M., Leibowitz, M. H., McLean, D. A., & Parry, H. (1995) · Cell · doi:10.1016/0092-8674(95)90374-7 · Cited by 836
Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6
Malumbres, M., Sotillo, R., Santamarı́a, D., Galán, J., Cerezo, A., Ortega, S., Dubus, P., & Barbacid, M. (2004) · Cell · doi:10.1016/j.cell.2004.08.002 · Cited by 793
If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells
Roninson, I. B., Broude, E. V., & Chang, B.-D. (2001) · Drug Resistance Updates · doi:10.1054/drup.2001.0213 · Cited by 725
CYCLINS AND CELL CYCLE CHECKPOINTS
Johnson, D. G., & Walker, C. L. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.295 · Cited by 719
Expression and amplification of cyclin genes in human breast cancer.
Buckley, M. F., Sweeney, K. J. E., Hamilton, J. A., Sini, R. L., Manning, D. L., Nicholson, R. I., DeFazio, A., Watts, C. K. W., Musgrove, E. A., & Sutherland, R. L. (1993) · PubMed · Cited by 667
Mouse development and cell proliferation in the absence of D-cyclins
Kozar, K., Ciemerych, M. A., Rebel, V. I., Shigematsu, H., Zagozdzon, A., Sicinska, E., Geng, Y., Yu, Q., Bhattacharya, S., Bronson, R. T., et al. (2004) · Cell · doi:10.1016/j.cell.2004.07.025 · Cited by 647
How Cells Get the Right Chromosomes
Nicklas, R. B. (1997) · Science · doi:10.1126/science.275.5300.632 · Cited by 609
Carlson, B. A., Dubay, M., Sausville, E. A., Brizuela, L., & Worland, P. J. (1996) · PubMed · Cited by 580
Polo, a mitotic mutant of Drosophila displaying abnormal spindle poles
Sunkel, C. E., & Glover, D. M. (1988) · Journal of Cell Science · doi:10.1242/jcs.89.1.25 · Cited by 561
Graves, P. R., Yu, L., Schwarz, J. K., Gales, J., Sausville, E. A., O'Connor, P. M., & Piwnica-Worms, H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5600 · Cited by 544
Involvement of Brca1 in S-Phase and G 2 -Phase Checkpoints after Ionizing Irradiation
Xu, B., Kim, S.-T., & Kastan, M. B. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.10.3445-3450.2001 · Cited by 540
KREK, W. (1994) · Cell · doi:10.1016/0092-8674(94)90582-7 · Cited by 492
Proliferation of cancer cells despite CDK2 inhibition
Tetsu, O., & McCormick, F. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00053-9 · Cited by 466
Flavopiridol Inhibits P-TEFb and Blocks HIV-1 Replication
Chao, S.-H., Fujinaga, K., Marion, J. E., Taube, R., Sausville, E. A., Senderowicz, A. M., Peterlin, B. M., & Price, D. H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000446200 · Cited by 455
Cell cycle-mediated drug resistance: an emerging concept in cancer therapy.
Shah, M. A., & Schwartz, G. K. (2001) · PubMed · Cited by 450
Self-citationCorrecting improper chromosome–spindle attachments during cell division
Lampson, M. A., Renduchitala, K., Khodjakov, A., & Kapoor, T. M. (2004) · Nature Cell Biology · doi:10.1038/ncb1102 · Cited by 434
Solit, D. B., Zheng, F. F., Drobnjak, M., Münster, P. N., Higgins, B., Verbel, D., Heller, G., Tong, W. P., Cordon‐Cardo, C., Agus, D. B., et al. (2002) · PubMed · Cited by 433
The molecular basis and potential role of survivin in cancer diagnosis and therapy
Altieri, D. C. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02243-2 · Cited by 412
Evans, W. K. (. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2004.08.002 · Cited by 405
Cdk inhibitors in development and cancer
Wade Harper, J., & Elledge, S. J. (1996) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(96)90011-8 · Cited by 399
Differential regulation of E2F transactivation by cyclin/cdk2 complexes.
Dynlacht, B. D., Flores, O., Lees, J. A., & Harlow, E. (1994) · Genes & Development · doi:10.1101/gad.8.15.1772 · Cited by 395
Lam, L. T., Pickeral, O. K., Peng, A. C., Rosenwald, A., Hurt, E. M., Giltnane, J. M., Averett, L. M., Zhao, H., Davis, R. E., Sathyamoorthy, M., et al. (2001) · Genome Biology · doi:10.1186/gb-2001-2-10-research0041 · Cited by 370
ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent
Gumireddy, K., Reddy, M. V. R., Cosenza, S. C., Nathan, R. B., Baker, S. J., Papathi, N., Jiang, J., Holland, J., & Reddy, E. P. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.009 · Cited by 367
The spindle assembly checkpoint
Rudner, A. D., & Murray, A. W. (1996) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(96)80077-9 · Cited by 365
McClue, S. J., Blake, D., Clarke, R., Cowan, A., Cummings, L., Fischer, P. M., MacKenzie, M., Melville, J., Stewart, K., Wang, S., et al. (2002) · International Journal of Cancer · doi:10.1002/ijc.10738 · Cited by 364
Potent Inhibition of Cdc2 Kinase Activity by the Flavonoid L86-8275
Losiewicz, M. D., Carlson, B. A., Kaur, G., Sausville, E. A., & Worland, P. J. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.1742 · Cited by 345
Giet, R., McLean, D., Descamps, S., Lee, M. J., Raff, J. W., Prigent, C., & Glover, D. M. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200108135 · Cited by 331
DNA Methylation: An Alternative Pathway to Cancer
Wajed, S. A., Laird, P. W., & DeMeester, T. R. (2001) · Annals of Surgery · doi:10.1097/00000658-200107000-00003 · Cited by 327
A p34cdc2 survival checkpoint in cancer
O'Connor, D. S., Wall, N. R., Porter, A. C. G., & Altieri, D. C. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00084-3 · Cited by 315
Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists
Chen, Y.-N. P., Sharma, S. K., Ramsey, T. M., Jiang, L., Martin, M. S., Baker, K., Adams, P. D., Bair, K. W., & Kaelin, W. G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4325 · Cited by 314
(2000) · PubMed · Cited by 314
The human mitotic checkpoint protein BubR1 regulates chromosome–spindle attachments
Lampson, M. A., & Kapoor, T. M. (2005) · Nature Cell Biology · doi:10.1038/ncb1208 · Cited by 311
Kotani, S., Tugendreich, S., Fujii, M., Jorgensen, P.-M., Watanabe, N., Hoog, C., Hieter, P., & Todokoro, K. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80037-4 · Cited by 304
Xu, M., Sheppard, K. A., Peng, C. Y., Yee, A. S., & Piwnica-Worms, H. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.12.8420 · Cited by 293
Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms
Sausville, E. A., Arbuck, S. G., Messmann, R., Headlee, D., Bauer, K. S., Lush, R. M., Murgo, A., Figg, W. D., Lahusen, T., Jaken, S., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2319 · Cited by 291
Carlson, B., Lahusen, T. J., Singh, S., Loaiza‐Perez, A., Worland, P. J., Pestell, R. G., Albanese, C., Sausville, E. A., & Senderowicz, A. M. (1999) · PubMed · Cited by 287
Byrd, J. C., Shinn, C., Waselenko, J. K., Fuchs, E. J., Lehman, T. A., Nguyen, P. L., Flinn, I. W., Diehl, L. F., Sausville, E., & Grever, M. R. (1998) · Blood · doi:10.1182/blood.v92.10.3804 · Cited by 283
Mutations in the kinesin-like protein Eg5 disrupting localization to the mitotic spindle
Sawin, K. E., & Mitchison, T. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.10.4289 · Cited by 271
Polo‐like kinase 1 (PLK1) is overexpressed in primary colorectal cancers
Takahashi, T., Sano, B., Nagata, T., Kato, H., Sugiyama, Y., Kunieda, K., Kimura, M., Okano, Y., & Saji, S. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01411.x · Cited by 265
Kitada, S., Zapata, J. M., Andreeff, M., & Reed, J. C. (2000) · Blood · doi:10.1182/blood.v96.2.393 · Cited by 264
Bible, K. C., & Kaufmann, S. H. (1997) · PubMed · Cited by 258
Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis.
Wall, N. R., O’Connor, D. S., Plescia, J., Pommier, Y. G., & Altieri, D. C. (2003) · PubMed · Cited by 252
Patel, V, Senderowicz, A. M., Pinto, D., Igishi, T., Raffeld, M., Quintanilla-Martinez, L., Ensley, J. F., Sausville, E. A., & Gutkind, J. S. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3661 · Cited by 246
Antitumor Activity of a Kinesin Inhibitor
Sakowicz, R., Finer, J. T., Beraud, C., Crompton, A., Lewis, E., Fritsch, A., Lee, Y., Mak, J., Moody, R., Turincio, R., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3839 · Cited by 241
Spindle assembly and the art of regulating microtubule dynamics by MAPs and Stathmin/Op18
Andersen, S. S. L. (2000) · Trends in Cell Biology · doi:10.1016/s0962-8924(00)01786-4 · Cited by 210
Stadler, W. M., Vogelzang, N. J., Amato, R., Sosman, J., Taber, D., Liebowitz, D., & Vokes, E. E. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.2.371 · Cited by 208
Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C.
Wender, P. A., Cribbs, C. M., Koehler, K. F., Sharkey, N. A., Herald, C. L., Kamano, Y., Pettit, G. R., & Blumberg, P. M. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.19.7197 · Cited by 201
Fuse, E., Tanii, H., Kurata, N., Kobayashi, H., Shimada, Y., Tamura, T., Sasaki, Y., Tanigawara, Y., Lush, R. D., Headlee, D. J., et al. (1998) · PubMed · Cited by 200
Schwartz, G. K., Ilson, D., Saltz, L., O’Reilly, E., Tong, W., Maslak, P., Werner, J., Perkins, P., Stoltz, M., & Kelsen, D. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.7.1985 · Cited by 196
Self-citationAction of camptothecin on mammalian cells in culture.
Li, L.-H., Fraser, T. J., Olin, E. J., & Bhuyan, B. K. (1972) · PubMed · Cited by 193
König, A., Schwartz, G. K., Mohammad, R. M., Al-Katib, A., & Gabrilove, J. L. (1997) · Blood · doi:10.1182/blood.v90.11.4307 · Cited by 191
Self-citationRegulation of transcription elongation by phosphorylation
Kobor, M. S., & Greenblatt, J. (2002) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(02)00457-8 · Cited by 187
Philip, P. A., Rea, D., Thavasu, P., Carmichael, J., Stuart, N. S. A., Rockett, H., Talbot, D. C., Ganesan, T., Pettit, G. R., Balkwill, F., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.22.1812 · Cited by 187
Chemistry and clinical biology of the bryostatins
Mutter, R., & Wills, M. (2000) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(00)00150-4 · Cited by 178
Shapiro, G. I., Supko, J. G., Patterson, A., Lynch, C., Lucca, J. V., Zacarola, P. F., Muzikansky, A., Wright, J. R., Lynch, T. J., & Rollins, B. J. (2001) · PubMed · Cited by 175
Motwani, M., Delohery, T. M., & Schwartz, G. K. (1999) · PubMed · Cited by 173
Self-citationHsp90 Inhibition Depletes Chk1 and Sensitizes Tumor Cells to Replication Stress
Arlander, S. J. H., Eapen, A. K., Vroman, B. T., McDonald, R. J., Toft, D. O., & Karnitz, L. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m309054200 · Cited by 169
Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control
Oelgeschläger, T. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10058 · Cited by 169
Fritz, B., Schubert, F., Wrobel, G., Schwäenen, C., Weßendorf, S., Neßling, M., Korz, C., Rieker, R. J., Montgomery, K. T., Kucherlapati, R., et al. (2002) · PubMed · Cited by 162
Yu, Q., Rose, J. H. L., Zhang, H., Takemura, H., Kohn, K. W., & Pommier, Y. G. (2002) · PubMed · Cited by 158
TAKAHASHI, I., Saitoh, Y., Yoshida, M., Sano, H., Nakano, H., Morimoto, M., & Tamaoki, T. (1989) · The Journal of Antibiotics · doi:10.7164/antibiotics.42.571 · Cited by 158
Akiyama, T., Yoshida, T., Tsujita, T., Shimizu, M., Mizukami, T., Okabe, M., & Akinaga, S. (1997) · PubMed · Cited by 152
BIRinging Chromosomes through Cell Division—And Survivin' the Experience
Reed, J. C., & Bischoff, J. R. (2000) · Cell · doi:10.1016/s0092-8674(00)00076-3 · Cited by 151
Hahntow, I. N., Schneller, F., Oelsner, M., Weick, K., Ringshausen, I., Fend, F., Peschel, C., & Decker, T. W. (2004) · Leukemia · doi:10.1038/sj.leu.2403295 · Cited by 147
A phase I study of intravenous bryostatin 1 in patients with advanced cancer
Prendiville, J., Crowther, D., Thatcher, N., Woll, P. J., Fox, B. W., McGown, A. T., Testa, N. G., Stern, P. L., McDermott, R. H., Potter, M., et al. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.352 · Cited by 146
Kim, E. H., Kim, S. U., Shin, D. Y., & Choi, K. S. (2004) · Oncogene · doi:10.1038/sj.onc.1207025 · Cited by 143
Polar expeditions — provisioning the centrosome for mitosis
Blagden, S. P., & Glover, D. M. (2003) · Nature Cell Biology · doi:10.1038/ncb0603-505 · Cited by 143
Shi, Z., Azuma, A., Sampath, D., Li, Y., Huang, P., & Plunkett, W. K. (2001) · PubMed · Cited by 139
Solit, D. B., She, Y., Lobo, J. M., Kris, M. G., Scher, H. I., Rosen, N. X., & Sirotnak, F. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1347 · Cited by 138
Jayson, G. C., Crowther, D., Prendiville, J., McGown, A. T., Scheid, C., Stern, P. L., Young, R., Brenchley, P. E., Chang, J., Owens, S. E., et al. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.356 · Cited by 125
Kawakami, K., Futami, H., Takahara, J., & Yamaguchi, K. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.0310 · Cited by 120
Salisbury, J. L., Whitehead, C. M., Lingle, W. L., & Barrett, S. L. (1999) · Biology of the Cell · doi:10.1016/s0248-4900(99)80086-0 · Cited by 119
Motwani, M., Jung, C. P., Sirotnak, F. M., She, Y., Shah, M. A., Gönen, M., & Schwartz, G. K. (2001) · PubMed · Cited by 116
Self-citationVarterasian, M. L., Mohammad, R. M., Eilender, D., Hulburd, K., Rodriguez, D. H., Pemberton, P. A., Pluda, J. M., Dan, M., Pettit, G. R., Chen, B. D. M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.56 · Cited by 114
Kortmansky, J. S., Shah, M. A., Kaubisch, A., Weyerbacher, A. R., Yi, S., Tong, W. P., Sowers, R. S., Gönen, M., O'Reilly, E. M., Kemeny, N. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.116 · Cited by 112
Self-citationCyclin D1 and mammary carcinoma: new insights from transgenic mouse models
Sutherland, R. L., & Musgrove, E. A. (2001) · Breast Cancer Research · doi:10.1186/bcr411 · Cited by 110
Human and Yeast Cdk-activating Kinases (CAKs) Display Distinct Substrate Specificities
Kaldis, P., Russo, A. A., Chou, H. S., Pavletich, N. P., & Solomon, M. J. (1998) · Molecular Biology of the Cell · doi:10.1091/mbc.9.9.2545 · Cited by 109
Phase II study of flavopiridol in patients with advanced colorectal cancer
Aklilu, M., Kindler, H. L., Donehower, R. C., Mani, S., & Vokes, E. E. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg343 · Cited by 108
Phosphorylation of E2F-1 by cyclin A-cdk2.
Kitagawa, M., Higashi, H., Suzuki‐Takahashi, I., et al. (1995) · PubMed · Cited by 108
Jung, C. P., Motwani, M., & Schwartz, G. K. (2001) · PubMed · Cited by 106
Self-citationTse, A. N., & Schwartz, G. K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0841 · Cited by 102
Self-citationA Phase I Clinical Trial of the Sequential Combination of Irinotecan Followed by Flavopiridol
Shah, M. A., Kortmansky, J. S., Motwani, M., Drobnjak, M., Gönen, M., Yi, S., Weyerbacher, A. R., Cordon‐Cardo, C., Lefkowitz, R. A., Brenner, B., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2651 · Cited by 101
Self-citationCell cycle effects of gemcitabine
Cappella, P., Tomasoni, D., Faretta, M., Lupi, M., Montalenti, F., Viale, F., Banzato, F., D’Incalci, M., & Ubezio, P. (2001) · International Journal of Cancer · doi:10.1002/ijc.1351 · Cited by 93
Chang, G., Hsu, S., Tsai, J., Liang, F.-P., Lin, S.-Y., Sheu, G., & Chen, C. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.06.006 · Cited by 92
Deng, L., Ammosova, T., Pumfery, A. M., Kashanchi, F., & Nekhai, S. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111349200 · Cited by 86
The role of protein stability in the cell cycle and cancer
Elledge, S. J., & Harper, J. W. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(98)00005-5 · Cited by 86
Koumenis, C., & Giaccia, A. J. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.12.7306 · Cited by 86
Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells.
Motwani, M., Rizzo, C., Sirotnak, F. M., She, Y., & Schwartz, G. K. (2003) · PubMed · Cited by 81
Self-citationHsueh, C.-T., Kelsen, D. P., & Schwartz, G. K. (1998) · PubMed · Cited by 81
Self-citationSeventy-Two Hour Continuous Infusion Flavopiridol in Relapsed and Refractory Mantle Cell Lymphoma
Lin, T. S., Howard, O. M., Neuberg, D. S., et al. (2002) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190290016908 · Cited by 75
Asiedu, C. K., Biggs, J. R., Lilly, M. B., & Kraft, A. S. (1995) · PubMed · Cited by 74
UCN-01 Enhances the In Vitro Toxicity of Clinical Agents in Human Tumor Cell Lines
Monks, A. P., Harris, E. D., Vaigro-Wolff, A., Hose, C. D., Connelly, J. W., & Sausville, E. A. (2000) · Investigational New Drugs · doi:10.1023/a:1006313611677 · Cited by 73
An ATM-independent S-phase checkpoint response involves CHK1 pathway.
Zhou, X.-Y., Wang, X., Hu, B., Guan, J., Iliakis, G. E., & Wang, Y. (2002) · PubMed · Cited by 72
Tan, A. R., Yang, X., Berman, A. W., Zhai, S., Sparreboom, A., Parr, A. L., Chow, C., Brahim, J. S., Steinberg, S. M., Figg, W. D., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0025 · Cited by 72
Wallace, J. C., Jitrapakdee, S., & Chapman‐Smith, A. (1998) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(97)00147-7 · Cited by 71
Shah, M. A., Kemeny, N. E., Hummer, A., Drobnjak, M., Motwani, M., Cordon‐Cardo, C., Gönen, M., & Schwartz, G. K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2417 · Cited by 68
Self-citationEffect of bryostatin 1 on taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937)
Wang, S., Guo, C., Castillo, A., Dent, P., & Grant, S. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00188-9 · Cited by 63
Vrana, J. A., Saunders, A. M., Chellappan, S., & Grant, S. (1998) · Differentiation · doi:10.1046/j.1432-0436.1998.6310033.x · Cited by 62
Koutcher, J. A., Motwani, M., Zakian, K. L., Li, X. K., Matei, C., Dyke, J. P., Ballon, D., Yoo, H. H., & Schwartz, G. K. (2000) · PubMed · Cited by 60
Self-citationPoele, R. T., Okorokov, A. L., & Joel, S. P. (1999) · Oncogene · doi:10.1038/sj.onc.1202961 · Cited by 60
Schwartz, G. K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.18.341 · Cited by 59
Self-citationDrg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells.
Motwani, M., Sirotnak, F. M., She, Y., Commes, T., & Schwartz, G. K. (2002) · PubMed · Cited by 57
Self-citationMatranga, C. B., & Shapiro, G. I. (2002) · PubMed · Cited by 55
7-Hydroxystaurosporine (UCN-01) Inhibition of Akt Thr308 but not Ser473 Phosphorylation
Kondapaka, S. B., Zarnowski, M. J., Yver, D. R., Sausville, E. A., & Cushman, S. W. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0772 · Cited by 55
Gao, N., Dai, Y., Rahmani, M., Dent, P., & Grant, S. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.002014 · Cited by 52
Wang, S., Wang, Z., Boise, L., Dent, P., & Grant, S. (1999) · Leukemia · doi:10.1038/sj.leu.2401532 · Cited by 51
Jiang, J., Matranga, C. B., Cai, D. D., Latham, V. M., Zhang, X., Lowell, A. M., Martelli, F., & Shapiro, G. I. (2003) · PubMed · Cited by 47
Terret, C., Zanetta, S., Roche, H. H., Schellens, J. H. M., Faber, M. N., Wanders, J., Ravic, M., & Droz, J. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00128-x · Cited by 47
Cartee, L., Wang, Z., Decker, R. H., Chellappan, S., Fusaro, G., Hirsch, K. G., Sankala, H. M., Dent, P., & Grant, S. (2001) · PubMed · Cited by 45
Cartee, L., Smith, R. L., Dai, Y., Rahmani, M., Rosato, R. R., Almenara, J. A., Dent, P., & Grant, S. (2002) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12090-1 · Cited by 43
Banker, D. E., Groudine, M. T., Willman, C. L., Norwood, T., & Appelbaum, F. R. (1998) · Leukemia Research · doi:10.1016/s0145-2126(97)00174-4 · Cited by 40
Cloning and Characterization of Plx2 and Plx3, Two Additional Polo-like Kinases from Xenopus laevis
Duncan, P. I., Pollet, N., Niehrs, C., & Nigg, E. A. (2001) · Experimental Cell Research · doi:10.1006/excr.2001.5333 · Cited by 37
van Kesteren, C., Beijnen, J. H., & Schellens, J. H. M. (2002) · Anti-Cancer Drugs · doi:10.1097/00001813-200211000-00002 · Cited by 36
Robert, N. J., Leyland-Jones, B., Asmar, L., Belt, R. J., Ilegbodu, D., Loesch, D. M., Raju, R. N., Cobleigh, M., Albain, K. S., & Slamom, D. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.573 · Cited by 36
The S phase: Beginning, middle, and end: A perspective
Ford, H. L., & Pardee, A. B. (1998) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(1998)72:30/31+<1::aid-jcb2>3.0.co;2-e · Cited by 30
Vrana, J. A., Kramer, L. B., Saunders, A. M., Zhang, X.-F., Dent, P., Povirk, L. F., & Grant, S. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00077-5 · Cited by 22
Sequence dependent potentiation of gemcitabine by flavopiridol in human breast cancer cells
Ali, S. S., El-Rayes, B. F., Aranha, O., Sarkar, F. H., & Philip, P. A. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-2179-x · Cited by 20
White, J., Cassidy, J., Twelves, C. J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.3042 · Cited by 14
Coyne, J. C., Palmer, S. C., & Shapiro, P. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.221 · Cited by 12
New bugs in the human genome draft
Veitia, R. A. (2001) · Genome biology · doi:10.1186/gb-2001-2-11-reports0041 · Cited by 5
Cited by
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
Drug development from marine natural products
Molinski, T. F., Dalisay, D. S., Lievens, S. L., & Saludes, J. P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2487 · Cited by 1,186
Li-Weber, M. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.09.005 · Cited by 896
A robustness-based approach to systems-oriented drug design
Kitano, H. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2195 · Cited by 488
MADDIKA, S., ANDE, S., PANIGRAHI, S., PARANJOTHY, T., WEGLARCZYK, K., ZUSE, A., ESHRAGHI, M., MANDA, K., WIECHEC, E., & LOS, M. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.01.003 · Cited by 461
Metadata
- Authors
- Schwartz, G. K., & Shah, M. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-12-20
- Volume
- 23
- Issue
- 36
- Pages
- 9408-9421
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1988050012
- Cited by
- 817
- References
- 136
- FWCI
- 14.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.